ENPP1 blockade with a humanized monoclonal antibody enhances renal repair after acute kidney injury - PubMed
5 hours ago
- #renal repair
- #acute kidney injury
- #monoclonal antibody
- ENPP1 blockade with a humanized monoclonal antibody (hENPP1mAb) enhances renal repair after acute kidney injury (AKI).
- ENPP1 is highly expressed in diseased human kidneys and correlates with renal dysfunction. Genetic targeting in mice improved repair.
- hENPP1mAb administration in humanized mice increased tubular cell proliferation, improved glomerular filtration rate, reduced fibrosis, and rescued kidney function.
- The antibody boosts nucleotide metabolism and cellular energetics, alleviating cell cycle arrest and promoting proliferation.
- Single-cell transcriptomics revealed expanded effective repair signatures with hENPP1mAb treatment.
- In a GLP-compliant dose escalation study, hENPP1mAb was non-toxic and well-tolerated in non-human primates.
- ENPP1 is identified as a key regulator of AKI, with hENPP1mAb showing therapeutic potential through ectonucleotidase activity blockade.